"Buy" Stance12 May 2009 09:09
Charles Stanley initiated coverage of shares in drug developer Antisoma with a 'buy' stance. The broker argues that the company has a broad and diverse pipeline of oncology products, of which one has been approved, two are in Phase III trials and four more are at Phase I and II. Antisoma's key product is ASA404, a cancer tumour treatment drug which has been partnered with Novartis in a deal worth up to 890 million dollars. Two further pivotal studies on the drug are underway and will report in 2011. Another promising product is AS1413, a DNA intercalator in Phase III development, however the broker added, "We view this as a high risk project since the clinical data so far has been pretty sparse." Further data is expected in late 2010 or early 2011. Oral fludarabine another of the group's offerings, was approved by the FDA in December 2008 and this is due to be divested before Antisoma's June year end. The company’s other clinical projects are interesting but the broker has not included them in setting its valuation, although the brokers NPV model will begin capturing them as they move further through the development stages. The broker concluded, "Antisoma is currently funded through to mid-2010 (£52.7m net cash at December 2008) and the proceeds of the divestment should extend this by at least a year." Shares in the company finished 0.5p higher at 30.5p.